Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAMIS: Predictors of BP Response to Antihypertensive Therapy
NCT00457483Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2007
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hydrochlorothiazide and valsartan in primary hypertension (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Blood pressure response as determined by Ambulatory Blood Pressure Monitoring at 4 weeks and Patient characteristics that predict blood pressure response at 4 weeks. Started Aug 2007; status: completed.
02
Drugs
hydrochlorothiazidevalsartan
03
Conditions
primary hypertension
Beyond the preview
Go deeper on NCT00457483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00457483.